Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065379 | 0.87 | ALOX15 (0.61) | ALOX15ALDH1A1USP2TSHRTDP1 | |
| SCHEMBL10520940 | 0.79 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TSHRTDP1 | |
| SCHEMBL3117924 | 0.79 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TSHRTDP1 | |
| SCHEMBL1200047 | 0.79 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TSHRTDP1 | |
| SCHEMBL10520930 | 0.79 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TSHRTDP1 | |
| SCHEMBL3147442 | 0.79 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TSHRTDP1 | |
| Citronellol SCHEMBL1871004 | 0.79 | ALOX15 (1.00) | ALOX15ALDH1A1USP2TSHRTDP1 | |
| SCHEMBL9632904 | 0.79 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TSHRTDP1 | |
| SCHEMBL1200044 | 0.79 | ALOX15 (0.68) | ALOX15ALDH1A1USP2TSHRTDP1 | |
| Citronellol SCHEMBL21320 | 0.79 | ALOX15 (1.00) | ALOX15ALDH1A1USP2TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238828-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11633479-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-10369226-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013086354-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-4562292-A | INHIBITORS OF HYDROLYTIC ENZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1985-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
| US-11633479-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
| US-10369226-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALOX15 196/4885ALDH1A1 3151/4885USP2 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.